Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program
18 nov. 2019 17h16 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
Nkarta Therapeutics Named as a “Fierce 15” Biotechnology Company of 2019
23 sept. 2019 09h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
Nkarta Therapeutics Promotes Nadir Mahmood, Ph.D., to Chief Business Officer
18 sept. 2019 08h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
Nkarta Therapeutics Appoints Vice President of Regulatory Affairs
10 sept. 2019 08h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials
04 sept. 2019 08h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
Nkarta Therapeutics Presents Data at AACR Demonstrating Proprietary NK Cell Engineering and Expansion Technology Enhances Potency and Cytotoxicity of NK Cells
01 avr. 2019 16h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing engineered Natural Killer (NK) cell therapies to fight cancer,...
Nkarta Therapeutics Announces Appointment of Matthew Plunkett, Ph.D., as Chief Financial Officer
10 déc. 2018 08h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing engineered Natural Killer (NK) immune cells to fight cancer,...
Nkarta Therapeutics Appoints Kanya Rajangam, M.D., Ph.D, as Chief Medical Officer
27 nov. 2018 08h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model
09 nov. 2018 08h00 HE
|
Nkarta
NK cell potency and persistence significantly improved using cell engineering technology60% increase in cytotoxicity observed with Nkarta NK cells relative to control NK cellsSingle in vivo...
Nkarta Therapeutics Expands Management Team and Establishes New Corporate Headquarters
09 juil. 2018 08h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...